Behavioral effects of clozapine and dopamine receptor subtypes

Neuroscience and Biobehavioral Reviews

Volumn 21, Issue 5, 1997, Pages 531-558

  Josselyn, S A ^a,b   Miller, R ^c   Beninger, R J ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

Antipsychotic; Behavior; Clozapine; Dopamine; Schizophrenia

Indexed keywords

ADENYLATE CYCLASE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; RECEPTOR SUBTYPE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICHOLINERGIC EFFECT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SCHIZOPHRENIA; SEQUENCE HOMOLOGY;

ANIMALS; BEHAVIOR; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CLOZAPINE; HUMANS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 0030711630     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(96)00051-6     Document Type: Article

References (347)

1. Ahlenius S., Engel J. Potentiation by alpha-methyltyrosine of the suppression of food-reinforced lever-pressing behavior induced by antipsychotic drugs. Acta Pharmacol. Toxicol. 40:1977;115-125.
2. Al-Shabibi U.M.H., Doggett N.S. Clozapine's anti-choline property modulates its antistereotypic action in the mesolimbic system. J. Pharm. Pharmacol. 32:1980;359-361.
3. Altar C.A., Wasley A.M., Neale R.F., Stone G.A. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an auto-radiographic analysis in rat brain. Brain Res. Bull. 16:1986;517-525.
4. Anden N.E., Robenson A., Fuxe K., Hokfelt T. Evidence for dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. 19:1967;627-629.
5. Arnfred T., Randrup A. Cholinergic mechanisms in brain inhibiting amphetamine-induced stereotyped behavior. Acta Pharmacol. Toxicol. 26:1968;384-394.
6. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol. Toxicol. 51:1982;321-329.
7. Arnt J. Hyperactivity induced by stimulation of separate dopamine D-1 and D-2 receptors in rats with bilateral 6-OHDA, lesions. Life Sci. 37:1985;717-723.
8. Arnt J. Behavioral stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats. Eur. J. Pharmacol. 113:1985;79-88.
9. Arnt J., Christensen A.V., Hyttel J. Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 329:1985;101-107.
10. Arnt J., Hyttel J. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers, revealed by bilateral 6-hydroxydopamine lesions and by chronic reserpine treatment in rats. J. Neural Transm. 60:1984;205-223.
11. Arnt J., Hyttel J. Differential inhibition by dopamine D-1 and D-2 antagonists of circling behavior induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions. Eur. J. Pharmacol. 102:1984;349-354.
12. Arnt J., Hyttel J. Differential involvement of dopamine D1 and D2 receptors, in the circling behavior induced by apomorphine, SK and F 38393, pergolide and LY 17155 in 6-hydroxydopamine-lesioned rats. Psychopharmacology. 85:1985;346-352.
13. Arnt J., Hyttel J. Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinities in vitro. J. Neural Transm. 67:1986;225-240.
14. Arnt J., Hyttel J., Perregaard J. Dopamine D1 receptor agonists combined with the selective D2 agonist quinpirole facilitate the expression of oral stereotyped behavior in rats. Eur. J. Pharmacol. 133:1987;137-145.
15. Arnt J., Hyttel J., Meier E. Inactivation of dopamine D1 or D2 receptor differentially inhibits stereotypies induced by dopamine agonists in rats. Eur. J. Pharmacol. 155:1988;37-47.
16. Atrens D.M., Ljungberg T., Ungerstedt U. Modulation of reward and aversion processes in the rat diencephalon by neuroleptics: differential effects of clozapine and haloperidol. Psychopharmacology. 49:1976;97-100.
17. Baldessarini R.J. The 'neuroleptic' antipsychotic drugs. I. Mechanisms of action Postgrad. Med. 65:1979;108-111.
18. Barghon R., Protais P., Colboc O., Costentin J. Hypokinesia in mice and catalepsy in rats elicited by morphine associated with antidopaminergic agents, including atypical neuroleptics. Neurosci. Lett. 27:1981;69-73.
19. Barnes T.R.E., Gerlach J. D-1 receptor antagonists in schizophrenia. Psychopharmacology. 121:1995;287-288.
20. Barry H., Steenberg M.L., Manian A.A., Buckley J.P. Effects of chlorpromazine and three metabolites on behavioral responses in rats. Psychopharmacology. 34:1974;351-360.
21. Beninger R.J. The role of dopamine in locomotor activity and learning. Brain Res. Rev. 6:1983;173-196.
22. Beninger, R.J. The slow therapeutic action of antipsychotic drugs. In: Simon, P.; Soubrié P.; Wildlocher, D., eds. Animal models of psychiatric disorder: selected models of anxiety, depression and psychosis. Basel: Karger; 1988:36-51.
23. Beninger R.J. Dissociating the effects of altered dopaminergic function on performance and learning. Brain Res. Bull. 23:1989;365-371.
24. Beninger, R.J. Role of D1 and D2 receptors in learning. In: Waddington, J.L., ed. D1:D2 dopamine receptor interactions. London: Academic Press; 1993:115-157.
25. Beninger R.J., Cheng M., Hahn B.L., Hoffman D.C., Mazurksi E.J., Morency M.A., Ramm P., Stewart R.J. Effects of extinction, pimozide, SCH 23390, and metoclopramide on food-rewarded operant responding in rats. Psychopharmacology. 92:1987;343-349.
26. Beninger R.J., Hoffman D.C., Mazurksi E.J. Receptor subtype-specific dopaminergic agents and conditioned behavior. Neurosci. Biobehav. Rev. 13:1989;113-122.
27. Beninger R.J., Mazurski E.J., Hoffman D.C. Receptor subtype-specific dopaminergic agents and unconditioned behavior. Pol. J. Pharmacol. Pharm. 43:1990;507-528.
28. Billard W., Ruperto V., Crosby G., Iorio L.C., Barnett A. Characterization of the binding of 3H-SCH 23390, a selective D1 receptor antagonist ligand. in rat striatum. Life Sci. 35:1984;1885-1893.
29. Blackburn J.R., Phillips A.G. Blockade of acquisition of one-way conditioned avoidance responding by haloperidol and metoclopramide but not by thioridazine or clozapine: implications for screening new antipsychotic drugs. Psychopharmacology. 98:1989;453-459.
30. Borison R., Diamond B.I. Regional selectivity of neuroleptic drugs: an argument for site specificity. Brain Res. Bull. 11:1983;215-218.
31. Boyce S., Kelly E., Davis A., Fleminger S., Jenner P., Marsden C.D. SCH 23390 may alter dopamine-mediated motor behavior via striatal D1 receptors. Biochem. Pharmacol. 34:1985;1665-1669.
32. Bracha H.S. Abnormal rotation (circling) behavior: A dopamine related asymmetry. Preliminary findings in unmedicated and never-medicated schizophrenic patients. Biol. Psychiat. 22:1987;995-1003.
33. Bracha H.S., Livingston R.L., Clothier J., Linington B.B., Karson C.N. Correlation of severity of psychiatric patients' delusions with right hemispatial inattention (left turning behavior). Am. J. Psychiat. 150:1993;330-334.
34. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia: human and animal model studies. Arch. Gen. Psychiat. 47:1990;181-188.
35. Braun A.R., Chase T.N. Obligatory D1/D2 receptor interactions in the generation of dopamine agonist related behavior. Eur. J. Pharmacol. 131:1986;301-306.
36. Breese G.R., Mueller R.A. SCH 23390 antagonism of D2 dopamine agonist depends upon catecholaminergic neurons. Eur. J. Pharmacol. 113:1985;109-114.
37. Brier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., Carpenter W.T. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiat. 151:1994;20-26.
38. Britton D.R., Curzon P., MacKenzie R.G., Kebabian J.W., Williams J.E., Kerkman D. Evidence for involvement of both D1 and D2 receptors in maintaining cocaine self-administration. Pharmacol. Biochem. Behav. 39:1991;911-915.
39. Britton D.R., Curzon P., Yahiro L., Buckley M., Tufano M., Nadzan A. Evaluation of a stable CCK agonist (A68552) in conditioned avoidance responding in mice, rats, and primates: comparison with typical and atypical antipsychotics. Pharmacol. Biochem. Behav. 43:1992;69-376.
40. Burt D.R., Creese I., Synder S.H. Anti-schizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 196:1977;326-327.
41. Buus Lassen J. Inhibition and potentiation of apomorphine-induced hypermotility in rats by neuroleptics. Eur. J. Pharmacol. 36:1976;385-393.
42. Calderon S.F., Sanberg P.R., Norman A.B. Quinolinic acid lesion of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy. Brain Res. 450:1988;403-407.
43. Callahan P.M., Appel J.B., Cunningham K.A. Dopamine DI and D2 mediation of the discriminative stimulus properties of D-amphetamine and cocaine. Psychopharmacology. 103:1991;50-55.
44. Cannon J.G. A comparison of clozapine, chlorpromazine, and thioridazine upon DRL performance in the squirrel monkey. Psychopharmacology. 64:1979;55-60.
45. Cannon J.G., Lippa A.S. Effects of clozapine, chlorpromazine and diazepam upon adjunctive and schedule controlled behaviors. Pharmacol. Biochem. Behav. 6:1977;581-587.
46. Cannon J.G., Lippa A.S. Use of DRL in differentiating anxiolytic and neuroleptic properties of CNS drugs. Pharmacol. Biochem. Behav. 6:1977;591-594.
47. Carlson J.H., Bergstrom D.A., Walters J.R. Neurophysiological evidence that D1 dopamine receptor blockade attenuates postsynaptic but not autoreceptor-mediated effects of dopamine agonists. Eur. J. Pharmacol. 123:1986;237-251.
48. Carter C.J., Pycock C.J. A study of sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy. Naunyn-Schmiedeberg's Arch. Pharmacol. 304:1978;135-138.
49. Casey D.E. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology. 99((Suppl)):1989;S47-S53.
50. Casey D.E. Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys. Psychopharmacology. 107:1992;18-22.
51. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 3:1983;1607-1619.
52. Chipkin R.E., Iorio L.C., McQuade R.D., Berger J.G., Barnett A. Pharmacological profile of SCH 39166: a dopamine D1 selective benzazepine with potential antipsychotic activity. J. Pharmacol. Exp. Ther. 247:1988;1093-1097.
53. Chipkin R.E., Latranyi M.B. Similarity of clozapine and SCH 23390 in reserpinized rats suggests a common mechanism of action. Eur. J. Pharmacol. 136:1987;371-375.
54. Christensen A.V., Arnt J., Hyttel J., Larsen J.J., Svendsen O. Pharmacological effects of a specific dopamine D1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci. 34:1984;1529-1540.
55. Claghorn J., Honigfeld G., Abuzzahab F.S., Wang R., Steinbook R., Tuason V., Klerman G. The risks and benefits of clozapine versus chlorpromazine. J. Clin. Psychopharmacology. 7:1987;377-384.
56. Clark D., White F.J. Review: D1 dopamine receptor - The search for a function: a critical evaluation of the D1/D2 receptor classification and its functional implications. Synapse. 1:1987;347-388.
57. Coffin V.L., Latranyi M.B., Chipkin R.E. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors. J. Pharmacol. Exp. Ther. 249:1989;769-774.
58. Coffin V.L., McHuch D., Chipkin R.E., Barnett A. SCH 39166, a potential antipsychotic drug, does not evoke movement disorders in Cebus monkeys. Neurochem. Int. 20:1992;141S-145S.
59. Colpaert F.C., Niemegeers C.J.E., Janssen P.A. Theoretical and methodological considerations on drug discrimination learning. Psychopharmacology. 46:1976;169-177.
60. Colpaert F.C., Niemegeers C.J.E., Janssen P.A. Discriminative stimulus properties of cocaine, and D-amphetamine, and antagonism by haloperidol: a comparative study. Neuropharmacology. 17:1978;937-942.
61. Cook L., Weidley E. Behavioral effects of some psychopharmacological agents. Ann. NY Acad. Sci. 66:1957;740-752.
62. Cooper, J.R.; Bloom, F.E.; Roth, R.H. The biochemical basis of neuropharmacology. New York: Oxford University Press; 1991.
63. Corrigall W.A., Coen K.M. Cocaine self-administration is increased by both D1 and D2 dopamine antagonists. Pharmacol. Biochem. Behav. 39:1991;799-802.
64. Costall B., Naylor R.J. Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia. 43:1975;69-74.
65. Costall B., Naylor R.J. A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonize the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems. Eur. J. Pharmacol. 40:1976;9-19.
66. Courvoisier S., Fournel J., Ducrot R., Kolsky M., Koetschet P. Properties pharmacodynamique du chlorhydrate de chloro-3(di-methylamino-3-propyl)-10 phenothiazine. Arch. Int. Pharmacodyn. Ther. 92:1953;305-361.
67. Coward D.M., Imperato A., Urwyler S., White T.G. Biochemical and behavioral properties of clozapine. Psychopharmacology. 99((Suppl)):1989;S6-S12.
68. Crane G.E. Persistent dyskinesia. Br. J. Psychiat. 122:1973;395-405.
69. Creese I., Burt D.R., Snyder S. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
70. Creese I., Chen A. Selective D1 dopamine receptor increase following chronic treatment with SCH 23390. Eur. J. Pharmacol. 109:1985;127-128.
71. Cross A.J., Hewitt L., Slater P., Waddington J.L. Interaction of benzazepine enantiomers with rat brain serotonin receptors. Br. J. Pharmacol. 90((Suppl)):1987;244P.
72. Cuomo V., Cagiano R., Colonna M., Renna G., Racagni G. Influence of SCH 23390, a DA-1-receptor antagonist, on the behavioral responsiveness to small and large doses of apomorphine in rats. Neuropharmacology. 25:1986;1297-1300.
73. Daly S.A., Waddington J.L. Two directions of dopamine D1/D2 receptor interaction in studies of behavioral regulation: a finding generic to four new, selective dopamine D1 receptor antagonists. Eur. J. Pharmacol. 213:1992;251-258.
74. Daly S.A., Waddington J.L. Behavioral evidence for 'D1-like' dopamine receptor subtypes in rat brain using the new isochroman agonist A68930 and isoquinoline antagonist BW 737C. Psychopharmacology. 113:1993;45-50.
75. Daly S.A., Waddington J.L. The effects of clozapine on behavioural responses to the selective 'D1-like' dopamine receptor agonist, A68930, and to the selective 'D2-like' agonist, RU 24213. Br. J. Pharmacol. 113:1994;839-844.
76. Damsma G., Robertson G.S., Tham C., Fibiger H.C. Dopaminergic regulation of striatal acetylcholine release: importance of D1 and N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 259:1991;1064-1072.
77. Davidson A.B., Weidley E. Differential effects of neuroleptic and other psychotropic agents on acquisition of avoidance in rats. Life Sci. 18:1976;1279-1284.
78. Dawson V.L., Dawson T.M., Warnsley J.K. Muscarinic and dopaminergic receptor subtypes on striatal interneurons. Brain Res. Bull. 25:1990;903-912.
79. de Beaurepaire R., LaBelle A., Naber D., Jones B.D., Barnes T.R.E. An open trial of the D-1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology. 121:1995;323-327.
80. De la Chapelle A., Kari C., Nurtninen M., Hemberg S. Clozapine-induced agranulocytosis. Hum. Genet. 37:1977;183-194.
81. DenBoer J.A., van Megen H.J.G.M., Fleischhacker W.W., Louwerens J.W., Slaap B.R., Westenberg H.G.M., Burrows G.D., Srivastava O.N. Differential effects of the D1-DA receptor antagonist SCH 139166 on positive and negative symptoms of schizophrenia. Psychopharmacology. 121:1995;317-322.
82. Depoortere R.Y., Li D.R., Lane J.D., Emmett-Oglesby M.W. Parameters of self-administration of cocaine in rats under a progressive-ratio schedule. Pharmacol. Biochem. Behav. 45:1993;539-548.
83. DeWit H., Wise R.A. Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with noradrenergic blockers phentolamine and phenoxybenzamine. Can J. Physiol. 31:1978;195-203.
84. Domino, E.F.; Kovacic, B. Monkey model of tardive dyskinesia. In: Ban, T.A.; Pichot, P.; Poldinger, L.W., eds. Modern problems of pharmacopsychiatry, vol. 21. Basel: S. Karger; 1983:21-23.
85. Downes R.P., Waddington J.L. Grooming and vacuous chewing induced by SK and F 83959, an agonist of dopamine 'D1-like' receptors that inhibits dopamine-sensitive adenylyl cyclase. Eur. J. Pharmacol. 234:1993;135-136.
86. Dragunow M., Robertson G.S., Faull R.L.M., Robertson H.A., Jansen K. D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience. 37:1990;287-294.
87. Edmonds D.E., Gallistel C.R. Reward vs. performance in self-stimulation: III. Effects of performance variables on the reward summation function J. Comp. Physiol. Psychol. 87:1974;876-883.
88. Ellenbroek B.A. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol. Ther. 56:1993;1-78.
89. Ellenbroek B.A., Artz M.T., Cools A.R. The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur. J. Pharmacol. 196:1991;103-108.
90. Ellenbroek B.A., Peeters B., Honig W.M., Cools A.R. The paw test: a behavioral paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology. 93:1987;343-348.
91. Elliot P.J., Walsh D.M., Close S.R., Higgins G.A., Hayes A.G. Behavioral effects of serotonin agonists and antagonists in the rat and marmoset. Neuropharmacology. 29:1990;949-956.
92. Ezrin-Waters C., Seeman P. Haloperidol-induced tolerance to morphine catalepsy. Life Sci. 21:1977;419-422.
93. Fage D., Scatton B. Opposing effects of D1 and D2 receptor antagonists on acetylcholine levels in the rat striatum. Eur. J. Pharmacol. 129:1986;359-361.
94. Farde L., Nodrstrom A.-L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiat. 49:1992;538-544.
95. Farde L., Nordstrom A.-L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br. J. Psychiat. 160:1992;30-33.
96. Farde L., Wiesel F.A., Nordstrom A.-L., Sedvall G. D1 and D2 dopamine receptor occupancy during treatment with conventional an atypical neuroleptics. Psychopharmacology. 99((Suppl)):1989;S28-S31.
97. Faustman W., Fowler S., Walker C. Time course of chronic haloperidol and clozapine upon operant rate and duration. Eur. J. Pharmacol. 70:1981;65-70.
98. Faustman W.O., Fowler S.C. An examination of methodological refinements, clozapine and fluphenazine in the anhedonia paradigm. Pharmacol. Biochem. Behav. 17:1982;987-993.
99. Fenton H.M., Hall N.R., Liebman J.M. Intracranial self-stimulation response decrement patterns differentiate drug-induced performance deficits from effects on reward. Soc. Neurosci. Abstr. 8:1982;468.
100. Fenton H.M., Leszczak E., Gerhardt S., Liebman J.M. Evidence for heterogeneous rotational responsiveness to apomorphine, 3-PPP and SKF 38393 in 6-hydroxydopamine-denervated rats. Eur. J. Pharmacol. 106:1984;363-372.
101. Fenton H.M., Liebman J.M. Self-stimulation response decrement patterns differentiate clonidine, baclofen and dopamine antagonists from drugs causing performance deficits. Pharmacol. Biochem. Behav. 17:1982;1207-1212.
102. Fibiger H.C. Drugs and reinforcement mechanisms: a critical review of the catecholamine theory. A. Rev. Pharmacol. Toxicol. 18:1978;37-56.
103. Fischer-Cornelssen K.A., Ferner U.J. An example of European multicenter trials: multispectral analysis of clozapine. Psychopharmacol. Bull. 12:1976;34-39.
104. Fletcher G.H., Starr M.S. Topography of dopamine behaviors mediated by D1 and D2 receptors revealed by intrastriatal injections of SKF 38393, lisuride and apomorphine in rats with a unilateral-induced lesions. Neuroscience. 20:1987;589-597.
105. Fog R. Role of the corpus striatum in typical behavioral effects in rats produced by both amphetamine and neuroleptic drugs. Acta Pharmacol. Toxicol. 25:1967;5965.
106. Fog R. On stereotypy and catalepsy: studies on the effects of amphetamines and neuroleptics in rats. Acta Neurol. Scand. 50:1972;1-9.
107. Fouriezos G., Wise R.A. Pimozide-induced extinction of intracranial self-stimulation: response patterns rule out motor or performance deficits. Brain Res. 103:1976;377-380.
108. Franklin K.B.J. Catecholamines and self-stimulation: reward and performance effects dissociated. Pharmacol. Biochem. Behav. 9:1978;813-820.
109. Gallistel C.R., Davis A.J. Affinity for the dopamine D2 receptor predicts neuroleptic potency in blocking the reinforcing effect of MFB stimulation. Pharmacol. Biochem. Behav. 19:1983;867-872.
110. Gallistel C.R., Karras D. Pimozide and amphetamine have opposing effects on the reward summation function. Pharmacol. Biochem. Behav. 20:1984;73-77.
111. Gardener E.L., Seeger T.F. Neurobehavioral evidence for mesolimbic specificity of action by clozapine: studies using electrical intracranial self-stimulation. Biol. Psychiat. 18:1993;1357-1362.
112. Gerber G.J., Sing J., Wise R.A. Pimozide attenuates lever pressing for water reinforcement in rats. Pharmacol. Biochem. Behav. 14:1981;201-205.
113. Gerhardt S., Gerber R., Liebman J.M. SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models. Life Sci. 37:1985;2355-2363.
114. Gerlach J., Andersen J., Clemmensen L., Haffner F, Lublin H. Antipsychotic efficacy of D1 receptor antagonists evaluated in primates (NNC 01-0756) and in a phase II clinical study (NNC 01-0687). Neuropsychopharmacol. 10:1994;237S.
115. Gerlach J., Casey D.E. Tardive dyskinesia. Acta Psychiat. Scand. 77:1988;369-378.
116. Gerlach, J.; Kistrup, K.; Korsgaard, S. Effects of selective D1 and D2 dopamine receptor antagonists and agonists in Cebus monkeys: implications for acute and tardive dyskinesias. In: Dahl, S.G.; Gram, L.S.; Paul, S.N.; Potter, W.V., eds. Clinical pharmacology in psychiatry (Psychopharmacology Series vol. 3). Berlin: Springer; 1987:236-242.
117. Gershanik O., Heikkila R.E., Duvoisin R.C. Behavioral correlations of dopamine receptor activation. Neurology. 33:1983;1489-1492.
118. Gessa G.L., Canu A., Del Zompo M., Burrai C., Serra G. Lack of acute antipsychotic effect of SCH 23390, a selective dopamine D1 receptor antagonist. Lancet. 337:1991;854-855.
119. Gessa G.L., Porceddu M.L., Collu M., Mervi M., Mervi G., Ongini E., Biggio O. Sedation and sleep induced by high doses of apomorphine after blockage of D1 receptors by SCH 23390. Eur. J. Pharmacol. 109:1985;269-274.
120. Geyer M., Swerdlow N.K., Mansbach R.S., Braff D.L. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Neurosci. Biobehav. Rev. 25:1990;485-498.
121. Giardino L., CaIza L., Piazza P.V., Amato G. Multiple neurochemical action of clozapine: a quantitative autoradiographic study of DA 2, opiate and benzodiazepine receptors in the rat brain after long-term treatment. J. Neural Transm. 83:1991;189-203.
122. Goas J.A., Boston J.E.J. Discriminative stimulus properties of clozapine and chlorpromazine. Pharmacol. Biochem. Behav. 8:1978;235-241.
123. Gower A.S., Marriot A.S. Pharmacological evidence for the subclassification of central dopamine receptors in the rat. Br. J. Pharmacol. 77:1982;185-194.
124. Grabowska-Anden A., Anden N.E. Stimulation of postsynaptic DA-2 receptors produces jerks in reserpine-treated rats. J. Pharmac. Pharmacol. 35:1983;543-545.
125. Graham F. The more or less startling effects of weak prestimuli. Psychophysiology. 12:1975;238-248.
126. Griffith R.W., Saameli K. Clozapine and agranulocytosis. Lancet. 2:1975;657.
127. Gunne L.M., Andersson U., Bondesson J., Johansson P. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol. Biochem. Behav. 25:1986;897-901.
128. Guyenet P.G., Agid Y., Javoy F., Beaujouan J.C., Rossier J., Glowinski J. Effects of dopaminergic receptor agonists and antagonists on the activity of neo-striatal cholinergic system. Brain Res. 84:1975;227-244.
129. Hansen L., Gerlach J. Dopamine 1 and 2 receptor interaction in the development of dystonia and hypersensibility in Cebus monkeys. Biol. Psychiat. 29:1991;275S.
130. Heal D.J., Czudek C., Buckett R. Common profile of D1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnover. Progr. Neuro-Psychopharmacol. Biol. Psychiat. 18:1994;803-821.
131. Herrera-Marschitz M., Ungerstedt U. Effect of the dopamine D1 antagonist SCH 23390 on rotation behavior induced by apomorphine and pergolide in 6-hydroxydopamine denervated rats. Eur. J. Pharmacol. 109:1985;349-354.
132. Hoffman D.C., Beninger R.J. The D1 dopamine receptor antagonist, SCH 23390 reduces locomotor activity and rearing in rats. Pharmacol. Biochem. Behav. 22:1985;341-342.
133. Hoffman D.C., Beninger R.J. The effects of selective dopamine D1 or D2 receptor antagonists on the establishment of agonist-induced place conditioning in rats. Pharmacol. Biochem. Behav. 33:1989;273-279.
134. Hoffman D.C., Donavon H. Does the atypical antipsychotic clozapine block the rewarding properties of amphetamine? Soc. Neurosci. Abstr. 17:1991;686.
135. Hoffman D.C., Donavon H. D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia. Psychopharmacology. 115:1994;447-453.
136. Hoffman D.C., Donavon H., Cassella J.V. The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology. 111:1993;339-344.
137. Hoffman H.S., Ison J.R. Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input Psychol. Rev. 87:1980;175-189.
138. Honma T., Fukushima H. Correlation between catalepsy and dopamine decrease in the rat striatum induced by neuroleptics. Neuropharmacology. 15:1976;601-607.
139. Honma T., Fukushima H. Effects of bilateral lesions in the striatum or nucleus accumbens on the cataleptogenic activity of neuroleptics in rats. Japan. J. Pharmacol. 28:1978;231-238.
140. Honma T., Fukushima H. The involvement of serotonergic neurons in the central nervous system as the possible mechanism for slow head-shaking behavior induced by methamphetamine in rats. Psychopharmacology. 65:1979;155-159.
141. Horvitz J.C., Ettenberg A. Haloperidol blocks the response-reinstating effects of food reward: a methodology for separating neuroleptic effects on reinforcement and motor processes. Pharmacol. Biochem. Behav. 31:1989;861-865.
142. Hubner C.B., Moreton J.E. Effects of selective D1 and D2 dopamine antagonists on cocaine self-administration in the rat. Psychopharmacology. 105:1991;151-156.
143. Hytell J. SCH 23390: The first selective dopamine D1 antagonist. Eur. J. Pharmacol. 91:1983;153-154.
144. Iorio L.C., Barnett A., Leitz F.H., Houser V.R., Korduba C.A. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther. 225:1983;462-468.
145. Jackson D.M., Hashizume M. Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D1 receptors are stimulated with SKF 38393. Psychopharmacology. 90:1986;147-149.
146. Janssen P.A.L., Niemegeers C.J.E., Schellekens K.H. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data. Arzneim-Forsch Drug Res. 15:1965;104-117.
147. Janssen, P.A.J.; van Bever, W.F.M. Structure-activity relationships of the butyrophenones and diphenylbutylpiperidines. In: Iversen, L.L.; Iversen, S.D.; Snyder, S.H., eds. Neuroleptics and schizophrenia. New York: Raven Press; 1978:1-35.
148. Jaskiw G.E., Hussain G., Meltzer H.Y. Frontal cortex lesions modify the cataleptogenic properties of haloperidol but not of clozapine. Biol. Psychiat. 34:1993;188-190.
149. Jenner P., Marsden C.D. Is the dopamine hypothesis of tardive dyskinesia completely wrong? Trends Neurosci. 9:1986;259-261.
150. Johansson P., Casey D.E., Gunne L.M. Dose-dependent increases in spontaneous chewing rates during long-term administration of haloperidol but not clozapine. Psychopharmacol. Bull. 22:1986;1017-1019.
151. Kaempf G.L., Porter J.H. Differential effects of pimozide and clozapine on schedule-controlled and scheduled-induced behaviors after acute and chronic administration. J. Pharmacol. Exp. Ther. 243:1987;437-445.
152. Kamien J.B., Woolverton W.L. Failure of SCH 23390 to function as a discriminative stimulus in rats. Pharmacol. Biochem. Behav. 34:1989;337-340.
153. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for treatment-resistant schizophrenics. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiat. 45:1988;789-796.
154. Kane J.M. Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. Drugs. 46:1993;585-593.
155. Karle J., Clemmensen L., Hansen L., Anderson M., Anderson J., Fensbo C., SlothNielsen M., Skrumsager B.K., Lublin H., Gerlach J. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology. 121:1995;328-330.
156. Karlsson P., Smith L., Farde L., Harnryd C., Sedvall G., Wiesel F.A. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH 31966 in acutely ill schizophrenic patients. Psychopharmacology. 121:1995;309-317.
157. Kebabiann J.W., Calne D.B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
158. Klawans H.L., Rubovits R., Patel C., Weiner W.J. Cholinergic and anti-cholinergic influences on amphetamine-induced stereotyped behavior. J. Neurol. Sci. 17:1972;303-308.
159. Koob G.F., Le H.T., Creese I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-admistration in the rat. Neurosci. Lett. 79:1987;315-320.
160. Kosten T.A., Nestler E.J. Clozapine attenuates cocaine conditioned place preference. Life Sci. 55:1994;9-14.
161. Kurumiya S., Nakajima S. Dopamine D1 receptors in the nucleus accumbens: involvement in the reinforcing effect of tegmental stimulation. Brain Res. 448:1988;1-6.
162. Lacosta S., Roberts D.C. MDL 7222, ketanserin and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine. Pharmacol. Biochem. Behav. 44:1993;161-165.
163. LaHoste G.L., Marshall J.F. The role of dopamine in the maintenance and breakdown of D1/D2 synergism. Brain Res. 611:1993;108-116.
164. Lang A., Vasar E., Soosaar A., Harro J. The involvement of sigma and phencyclidine receptors in the action of antipsychotic drugs. Pharmacol. Toxicol. 71:1992;132-138.
165. Leone P., DiChiara G. Blockade of D1 receptors by SCH 23390 antagonized morphine- and amphetamine-induced place preference conditioning. Eur. J. Pharmacol. 135:1987;251-254.
166. Liebman J., Neale R. Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects. Psychopharmacology. 68:1980;25-29.
167. Liebman J.M. Discriminating between reward and performance: a critical review of intracranial self-stimulation methodology. Neurosci. Biobehav. Rev. 7:1983;45-72.
168. Liebman J.M., Hall N., Prowse J. Effects of various catecholamine receptor antagonists, muscle relaxation and physical hindrance on shuttlebox self-stimulation. Pharmacol. Biochem. Behav. 16:1982;785-790.
169. Ljungberg T. Blockade by neuroleptics of water intake and operant responding for water in the rat: anhedonia, motor deficit or both? Pharmacol. Biochem. Behav. 27:1987;341-350.
170. Ljungberg T. Scopolamine reverses haloperidol-attenuated lever-pressing for water but not haloperidol-attenuated water intake in the rat. Pharmacol. Biochem. Behav. 29:1988;205-208.
171. Ljungberg T. Effects of the dopamine D-1 antagonist SCH 23390 on water intake, water-rewarded operant responding and apomorphine induced decreases in water intake in rats. Pharmacol. Biochem. Behav. 33:1989;709-712.
172. Ljungberg T. Differential attenuation of water intake and water-rewarded operant responding by repeated administration of haloperidol and SCH 23390 in the rat. Pharmacol. Biochem. Behav. 35:1990;111-115.
173. Ljungberg T., Ungerstedt U. Apomorphine-induced locomotion and gnawing: evidence that the experimental design greatly influences gnawing while locomotion remains unchanged. Eur. J. Pharmacol. 46:1977;147-151.
174. Ljungberg T., Ungerstedt U. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action. Psychopharmacology. 56:1978;239-247.
175. Ljungberg T., Ungerstedt U. Evidence that the different properties of haloperidol and clozapine are not explained by differences in anticholinergic potency. Psychopharmacology. 60:1979;303-307.
176. Loh E.A., Fitch T., Vickers G., Roberts D.C. Clozapine increases breaking points on a progressive-ratio schedule reinforced by intravenous cocaine. Pharmacol. Biochem. Behav. 42:1992;559-562.
177. Loh E.A., Roberts D.C.S. Breakpoints on a progressive-ratio schedule reinforced by intravenous cocaine increase following depletion of forebrain serotonin. Psychopharmacology. 101:1990;262-266.
178. Longoni R., Spina L., DiChiara G. Permissive role of D1 receptor stimulation for the expression of D2 mediated behavioral responses: a quantitative phenomenological study in rats. Life Sci. 41:1987;2135-2145.
179. Lynch M.R. Schizophrenia and the D1 receptor: focus on negative symptoms. Progr. Neuropsychopharmacol. Biol. Psychiat. 16:1992;797-832.
180. MacEwan, G.W., New antipsychotic medications: do research results relate to clinical practice?. Can. J. Psychiat., 38, 275-S79 1993.
181. Mailman R.B., Schulz D.W., Lewis M.H., Staples L., Rollema H., Dehaven D.L. SCH 23390, a selective D1 dopamine antagonist with potent D2 behavioral actions. Eur. J. Pharmacol. 101:1984;159-160.
182. 3H)g-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not other antipsychotics. Eur. J. Pharmacol. 256:1994;211-214.
183. Maldonado R., Robledo R., Chover A.J., Caine S.B., Koob G.F. D1 dopamine receptors in the nucleus accumbens modulate cocaine selfadministration in the rat. Pharmacol. Biochem. Behav. 45:1993;239-242.
184. Mansbach R.S., Geyer M.A., Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology. 94:1988;507-514.
185. Marin C., Parashos S.A., Kapitzoglou-Logothetis V., Peppe A., Chase T.N. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol. Biochem. Behav. 45:1993;195-200.
186. Mason S.T., Beninger R.J., Fibiger H.C., Phillips A.G. Pimozide-induced suppression of responding: evidence against a block of food reward. Pharmacol. Biochem. Behav. 12:1980;917-923.
187. McCauley P.G., O'Boyle K.M., Waddington J.L. Dopamine-induced reduction in the density of guanine nucleotide-sensitive D1 receptors in human postmortem brain, in the absence of apparent D1:D2 interactions. Neuropharmacology. 34:1995;777-783.
188. McEvoy J.P., Hogarty G.E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiat. 48:1991;739-745.
189. McGhie A., Chapman J. Disorders of attention and perception in early schizophrenia. Br. J. Med. Psychol. 34:1961;102-116.
190. McQuade R.D., Duffy R.A., Coffin V.L., Barnett A. In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity. Eur. J. Pharmacol. 215:1992;29-34.
191. Meller E., Kuga S., Friedhoff A.L., Goldstein M. Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist. Life Sci. 36:1985;1857-1864.
192. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99 (Suppl):1989;S18-S27.
193. 2 pki values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
194. Meltzer H.Y., Stockmeier C.A. In vivo occupancy of dopamine receptors by antipsychotic drugs. Arch. Gen. Psychiat. 49:1992;588-589.
195. Meyer M.E., Cottrell G.A., Van Hartesveldt C.A. Dopamine D1 antagonists potentiate the duration of bar and cling catalepsy and the dorsal immobility response in rats. Pharmacol. Biochem. Behav. 41:1992;507-510.
196. Meyer M.E., Cottrell G.A., Van Hartesveldt C.A., Potter T.J. Effects of dopamine D1 antagonists SCH 23390 and SK and F 83566 on locomotor activities in rats. Pharmacol. Biochem. Behav. 44:1993;429-432.
197. Miller R. Major psychosis and dopamine: controversial features and some suggestions. Psychol. Med. 14:1984;779-789.
198. Miller R. The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness. Psychopharmacology. 92:1987;405-415.
199. Miller R. Striatal dopamine in reward and attention: a system for understanding the symptomatology of acute schizophrenia and mania. Int. Rev. Neurobiol. 35:1993;161-278.
200. Miller R., Beninger R.J. On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animal with unilateral depletion of striatal dopamine. Progr. Neurobiol. 36:1991;299-356.
201. Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiat. 34:1993;713-738.
202. Miller R., Wickens J.R., Beninger R.J. Dopamine D1 and D2 receptors, in relation to reward and performance: a case for the D1 receptor as a primary site of therapeutic action of neuroleptic drugs. Progr. Neurobiol. 34:1990;143-184.
203. Miller R.J., Hiley C.R. Antimuscarinic properties of neuroleptics and drug-induced parkinsonism. Nature. 248:1974;596-597.
204. Molloy A.G., O'Boyle K.M., Pugh M.T., Waddington J.L. Locomotor behaviors in response to new selective D1 and D2 dopamine receptor agonists, and the influence of selective antagonists. Pharmacol. Biochem. Behav. 25:1986;249-253.
205. Molloy A.G., Waddington J.L. Dopaminergic behavior stereo-specifically promoted by the D1 agonist R-SKF 38393 and selectively blocked by the agonist SCH 23390. Psychopharmacology. 82:1984;409-410.
206. Molloy A.G., Waddington J.L. Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SK and F 38393 and to apomorphine: differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metoclopramide. Eur. J. Pharmacol. 108:1985;305-308.
207. Molloy A.G., Waddington J.L. The enantiomers of SK and F 83566, a new selective D-1 dopamine antagonist, stereospecifically block stereotyped behavior induced by apomorphine and by the selective D-2 agonist RU 24213. Eur. J. Pharmacol. 116:1985;183-186.
208. Moore N.A., Blackman A., Awere S., Leander J.D. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. Eur. J. Pharmacol. 237:1993;1-7.
209. Moore S., Kenyon P. Atypical antipsychotics, clozapine and sulpiride do not antagonise amphetamine-induced stereotyped locomotion. Psychopharmacology. 114:1994;123-130.
210. Morelli M., DiChiara G. Catalepsy induced by SCH 23390 in rats. Eur. J. Pharmacol. 117:1985;179-185.
211. Morency M.A., Beninger R.J. Dopaminergic substrates of cocaine-induced place conditioning. Brain Res. 399:1986;33-41.
212. Muller P., Seeman P. Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. Life Sci. 21:1977;1751-1758.
213. Murray A.M., Hyde T.M., Knable M.B., Herman M.M., Bigelow L.B., Carter J.M., Weinberger D.R., Kleinman J.E. Distribution of putative D4 receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15:1995;2186-2191.
214. Murray A.M., Waddington J.L. The induction of grooming and vacuous chewing by a series of selective D1 dopamine receptor agonist: two directions of D1:D2 interaction. Eur. J. Pharmacol. 160:1989;377-384.
215. Murray A.M., Waddington J.L. Further evidence for two directions of D1:D2 dopamine receptor interaction revealed concurrently in distinct elements of typical and atypical behavior: studies with new enantioselective D2 agonist LY 163502. Psychopharmacology. 98:1989;245-250.
216. Murray A.M., Waddington J.L. Behavioral indices of the interaction of clozapine with D1 and D2 dopamine receptors. Br. J. Pharmacol. 98 (Suppl):1989;814P.
217. Murray A.M., Waddington J.L. The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: behavioral indices. Eur. J. Pharmacol. 186:1990;79-86.
218. Nakajima S. Suppression of operant responding in the rat by dopamine D1 receptor blockade with SCH 23390. Physiol. Behav. 14:1986;111-114.
219. Nakajima S., Baker J.D. Effects of D2 dopamine receptor blockade with raclopride on intracranial self-stimulation and food-reinforced operant behavior. Psychopharmacology. 98:1989;330-333.
220. Nakajima S., Liu X., Lau C.L. Synergistic interaction of D1 and D2 dopamine receptors in the modulation of the reinforcing effect of brain stimulation. Behav. Neurosci. 107:1993;161-165.
221. Nakajima S., McKenzie G.M. Reduction of the rewarding effect of brain stimulation by a blockade of dopamine D1 receptor with SCH 23390. Pharmacol. Biochem. Behav. 24:1986;919-923.
222. Nakajima S., O'Regan N.B. The effects of dopaminergic agonists and antagonists on the frequency-response function for hypothalamic self-stimulation in the rat. Pharmacol. Biochem. Behav. 39:1991;465-468.
223. Nakuruma M., Carney J.M. Antagonism by CGS 8216 and Ro 15-1788, benzodiazepine antagonists, of the action of chlordiazepoxide on a timing behavior in rats. Pharmacol. Biochem. Behav. 21:1984;381-385.
224. Naylor R.J., Costall B. The relationship between the inhibition of dopamine uptake and the enhancement of amphetamine stereotypy. Life Sci. 10:1971;909-915.
225. Needham P.L., Skill M.L., Cowan A., Redfern R.J., Heal D.J. Reserpinization severs the cooperative but not appositional interaction between D1 and D2 receptors. Neuropharmacology. 32:1993;515-517.
226. Nielsen E.B. Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology. 94:1988;115-118.
227. Nielsen E.B., Jespen S.A. Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. Eur. J. Pharmacol. 11:1985;167-176.
228. Niemegeers C.J.E., Verbruggen F.J., Janssen P.A.J. The influence of various neuroleptic drugs on shock avoidance responding in rats. Psychopharmacology. 16:1969;161-174.
229. 2 receptor antagonists in schizophrenia: preclinical and clinical considerations. In: Racagni, G.; Brunello, N.; Fukeda, T., eds. Biological psychiatry. Amsterdam: Excepta Medica; 1992:535-537.
230. O'Boyle K.M., Molloy A.G., Mashurano M., Waddington J.L. Structural analogs of SCH 23390 as discriminators of dopamine receptor subtypes: behavioral interactions between D1 and D2 agonists and antagonists. Psychopharmacol. Bull. 22:1986;599-604.
231. O'Boyle K.M., Waddington J.L. Identification of the enantiomers of SK and F 83566 as specific and stereoselective antagonists at the striatal D1 dopamine receptor: comparisons with D2 enantioselectivity of Ro 22-1319. Eur. J. Pharmacol. 106:1984;219-220.
232. 3H)-piflutixol. Eur. J. Pharmacol. 105:1984;171-174.
233. O'Boyle K.M., Gavin K.T., Harrison N. Chronic antagonist treatment does not alter the mode of interaction of dopamine with rat striatal dopamine receptors. J. Receptor Res. 13:1993;329-339.
234. O'Dell S.J., La Hoste G.J., Widmark C.B., Shapiro R.M., Potkin S.G., Marshall J.F. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse. 6:1990;146-153.
235. Parsa M.A., Lahhah A.I., Ramirez L.F., Meltzer H.Y. Prolonged psychotic relapse after abrupt clozapine withdrawal. J. Clin. Psychopharmacol. 13:1993;154-155.
236. Peacock L., Lublin H., Gerlach J. The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur. J. Pharmacol. 186:1990;49-54.
237. Peng R.Y., Mansbach R.S., Braff D.L. A D2 dopamine receptor agonist disrupts sensorimotor gating in rats: implications for dopaminergic abnormalities in schizophrenia. Neuropsychopharmacology. 3:1990;211-218.
238. Peroutka S.J., Snyder S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic and histamine receptors to clinical potency. Am. J. Psychiat. 137:1980;1518-1522.
239. Pickens R., Harris W.C. Self-administration of D-amphetaraine by rats. Psychopharmacology. 12:1968;158-163.
240. Pickens R., Thompson T. Cocaine-reinforced behavior in rats: effects of reinforcement magnitude and fixed-ratio size. J. Pharmacol. Exp. Ther. 161:1968;122-129.
241. Porsolt R.B., Jalfre M. Neuroleptic induced acute dyskinesia in rhesus monkey. Psychopharmacology. 75:1981;16-20.
242. Prissen E.P.M., Ellenbroek B.A., Stamatovic B., Cools A.R. The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166. Eur. J. Pharmacol. 231:1993;275-280.
243. Pugh M.T., O'Boyle K.M., Molloy A.G., Waddington J.L. Effects of the putative D1 antagonist SCH 23390 on stereotyped behavior induced by the D2 agonist RU 24213. Psychopharmacology. 87:1985;308-312.
244. Reina, G.; Sacchi, C.; Aguggini, G. Analysis of antiemetic effects of sulpiride isomers in dogs. In: Spano, P.F.; Travucchi, M.; Corsin, G.U.; Gessa, G.L., eds. Sulpiride and other benzamides. New York: Raven Press; 1979:83-99.
245. Reynolds G.P., Mason S.L. Are striatal dopamine D4 receptors increased in schizophrenia? J. Neurochem. 63:1994;1576-1577.
246. Reynolds G.P., Mason S.L. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. Eur. J. Pharmacol. 281:1995;R5-R6.
247. Richelson E., Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur. J. Pharmacol. 130:1984;197-204.
248. Rigdon G.C., Viik K. Prepulse inhibition as a screening test for potential antipsychotics. Drug Dev. Res. 23:1991;91-99.
249. Roberts D.C.S., Vickers G. Atypical neuroleptics increase self-administration of cocaine: an evaluation of a behavioral screen for antipsychotic activity. Psychopharmacology. 82:1984;135-139.
250. Roberts D.C.S., Loh E.A., Vickers G. Self-administration of cocaine on a progressive ratio schedule in rats: dose-response relationship and effect of haloperidol pretreatment. Psychopharmacology. 97:1989;535-538.
251. Robertson A., MacDonald C. Atypical neuroleptics clozapine and thioridazine enhance amphetamine-induced stereotypy. Pharmacol. Biochem. Behav. 21:1984;97-101.
252. Robertson A., MacDonald C. The effects of some atypical neuroleptics on apomorphine-induced behaviors as a measure of their relative potencies in blocking presynaptic versus postsynaptic dopamine receptors. Pharmacol. Biochem. Behav. 24:1986;1639-1643.
253. Rompre P.R., Bauco P. GBR 1209 reverses the SCH 23390 inhibition of rewarding effects of brain stimulation. Eur. J. Pharmacol. 182:1990;181-184.
254. Rosengarten H., Schweitzer J.W., Friedhoff A.J. Selective dopamine D2 receptor reduction enhances a D1-mediated oral dyskinesia in rats. Life Sci. 39:1986;29-35.
255. Rosenzweig-Lipson S., Bergman J. Modification of the behavioral effects of the selective dopamine D2 agonist (+)-4-propyl-9-hydroxynapthoxazine by dopamine antagonists in monkeys. J. Pharmacol. Exp. Ther. 265:1993;1039-1046.
256. Roth B.L., Tandra S., Burgess L.H., Sibley D.R., Meltzer H.Y. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology. 120:1995;365-368.
257. Rupniak N.M., Hall M.D., Mann S., Fleminger S., Kilpatrick G., Jenner R., Marsden C.D. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem. Pharmacol. 34:1985;2755-2763.
258. Rupniak N.M., Jenner P., Marsden C.D. Cholinergic manipulation of perioral behavior induced by chronic neuroleptic administration in rats. Psychopharmacology. 79:1983;226-230.
259. Rupniak N.M., Kilpatrick G., Hall M.D., Jenner P., Marsden C.D. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride and clozapine in rats. Psychopharmacology. 84:1984;512-519.
260. 3H-Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds. Naunyn-Schmiedeberg's Arch. Pharmacol. 334:1986;125-132.
261. Sanger D.J. The effects of clozapine on shuttle-box avoidance responding in rats: comparisons with haloperidol and chlordiazepoxide. Pharmacol. Biochem. Behav. 23:1985;231-236.
262. Sanger D.J. Response decrement patterns after neuroleptic and non-neuroleptic drugs. Psychopharmacology. 89:1986;98-104.
263. Sanger D.J. The actions of SCH 23390, a D1 receptor antagonist, on operant and avoidance behavior in rats. Pharmacol. Biochem. Behav. 26:1987;509-513.
264. Sanger D.J., Blackman D.E. The effects of tranquilizing drugs on timing behavior in rats. Psychopharmacologia. 44:1975;153-156.
265. Sanger, D.J.; Blackman, D.E. Operant behavior and the effects of centrally acting drugs. In: Boulton, A.A.; Baker, G.B.; Greenshaw, A.J., eds. Psychopharmacology. Neuromethods, vol. 13. Clifton, NJ: Humana Press; 1989:299-348.
266. Sanger D.J., Key M., Blackman D.E. Differential effects of chlordiazepoxide and D-amphetamine on responding maintained by a DRL schedule of reinforcement. Psychopharmacologia. 38:1974;159-171.
267. Sanger D.J., Perrault G. Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats. J. Pharmacol. Exp. Ther. 272:1995;708-713.
268. Sayers A.C., Burki H.R., Ruch W., Asper H. Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects. Psychopharmacology. 51:1976;15-22.
269. Scatton B. Further evidence for the involvement of D2, but not D1, dopamine receptors in dopaminergic control of striatal cholinergic transmission. Life Sci. 31:1982;2883-2890.
270. Schaefer G.J., Michael R.P. Acute effects of neuroleptics on brain self-stimulation thresholds in rats. Psychopharmacology. 67:1980;9-15.
271. Schecter M.D. Effect of neuroleptics and tricyclic antidepressants upon damphetamine discrimination. Pharmacol. Biochem. Behav. 12:1980;1-5.
272. Schwarzlcopf S.B., Bruno J.R., Mitra T. Effects of haloperidol and SCH 23390 on acoustic stimuli and prepulse inhibition under basal and stimulated conditions. Progr. Neuro-Psychopharmacol. Biol. Psychiat. 17:1993;1023-1036.
273. Sebens J.B., Koch T., Ter Horst G.J., Korf J. Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur. J. Pharmacol. 273:1995;175-182.
274. See R.E., Chapman M.A. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur. J. Pharmacol. 263:1994;269-276.
275. See R.E., Ellison G. Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. Eur. J. Pharmacol. 181:1990;175-186.
276. Seeger T.F., Thal L., Gardner E.L. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol. Psychopharmacology. 76:1982;182-187.
277. Seeman P. Brain dopamine receptors. Pharmacol. Rev. 32:1980;229-313.
278. Seeman P. Tardive dyskinesia, dopamine receptors and neuroleptic damage to cell membranes. J. Clin. Psychopharmacol. 8 (Suppl):1988;53-59.
279. Seeman P. Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiat. Scand. 358 (Suppl):1990;14-20.
280. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 7:1992;261-284.
281. Seeman P., Chau-Wong M., Tedesco L., Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc. Natl Acad. Sci. USA. 72:1975;4376-4380.
282. Seeman P., Guan H.C., Van Tol H.H.M. Dopamine D4 receptors are elevated in schizophrenia. Nature. 365:1993;441-445.
283. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 188:1975;1217-1219.
284. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
285. Seeman P., Niznik H.B., Guan H.-C., Booth G., Ulpian C. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington's diseased brain. Proc. Natl Acad. Sci. USA. 86:1989;10156-10160.
286. Seeman R., Ulpian C. Neuroleptics have identical potencies in human brain limbic and putamen regions. Eur. J. Pharmacol. 94:1983;145-148.
287. 3H)nemonapride. J. Neurochem. 64:1995;1413-1415.
288. Seeman P., Van Tol H.H.M. Reply. J. Neurochem. 65:1995;2382-2383.
289. Selbie L.A., Hayes G., Shine J. The major dopamine D2 receptor: molecular analysis of the human D2A receptor subtype. DNA. 8:1989;683-689.
290. Shropshire A.T., Marquis K.L. Evaluating the paw test as a paradigm for differentiating between classical and atypical neuroleptics. Soc. Neurosci. Abstr. 17:1991;686.
291. Sibley D.R., Monsma F.L., Shen Y. Molecular neurobiology of dopaminergic receptors. Int. Rev. Neurobiol. 35:1993;391-415.
292. Snyder S.H., Greenberg D., Yamumura H.I. Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects. J. Psychiat. Res. 11:1974;91-95.
293. Sokoloff P., Giros B., Matres M.P., Bouthenet M.T., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
294. Sokoloff P., Matres M.P., Girosm B., Bouthenet M.L., Schwartz J.L. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem. Pharmacol. 43:1992;659-666.
295. Spealman R.D. Comparison of drug effects on responding punished by pressurized air or electric shock delivery in squirrel monkeys: pentobarbital, chlordiazepoxide, D-amphetamine and cocaine. J. Pharmacol. Exp. Ther. 209:1979;309-315.
296. Spealman R.D. Effects of some dibenzodiazepines on suppressed and nonsuppressed behavior of squirrel monkeys. Psychopharmacology. 85:1985;129-132.
297. Spealman R.D. Discriminative-stimulus effects of midazolam in squirrel monkeys: comparison with other drugs and antagonism by Ro 15-1788. J. Pharmacol. Exp. Ther. 235:1985;456-462.
298. Spealman R.D., Katz J.L. Some effects of clozapine on punished responding by mice and squirrel monkeys. J. Pharmacol. Exp. Ther. 212:1980;435-440.
299. Spealman R.D., Kelleher R.T., Goldberg S.R., DeWeese J., Goldberg D.M. Behavioral effects of clozapine: comparison with thioddazine, chlorpromazine, haloperidol and chlordiazepoxide in squirrel monkeys. J. Pharmacol. Exp. Ther. 224:1983;127-134.
300. Spyraki C., Fibiger H.C., Phillips A.G. Dopaminergic substrates of amphetamine-induced place preference conditioning. Brain Res. 253:1982;185-193.
301. Stadler H., Lloyd K.G., Gadea-Ciria M., Bartholini G. Enhanced striatal acetylcholine release by chlorpromazine and its reversal by apormorphine. Brain Res. 55:1973;476-480.
302. Starr B.C., Starr M.S. Grooming in the mouse is stimulated by the dopamine D1 agonist SK and F 38393 and by low doses of the D1 antagonist SCH 23390 but inhibited by dopamine D2 agonists, D2 antagonists and high doses of SCH 23390. Pharmacol. Biochem. Behav. 24:1986;837-840.
303. Stefanini E., Clement-Cornier Y. Detection of dopamine receptors in area postrema. Eur. J. Pharmacol. 74:1981;257-260.
304. Stein L., Ray O.S. Brain stimulation reward 'thresholds' self-determined in rat. Psychopharmacologia. 1:1960;251-256.
305. Stellar J.R., Kelley A.E., Corbett D. Effects of peripheral and central dopamine blockade on lateral hypothalamic self-stimulation: evidence for both reward and motor deficits. Pharmacol. Biochem. Behav. 18:1983;433-442.
306. Stoof J.C., De Boer T., Sminia P., Mulder A.H. Stimulation of D2 dopamine receptors in rat neostriatum inhibits release of acetylcholine and dopamine but does not affect the release of gamma-aminobutyric acid, glutamate or serotonin. Eur. J. Pharmacol. 84:1982;211-214.
307. Stoof J.C., Kebabian J.W. Two dopamine receptors: biochemistry, physiology and pharmacology. Science. 35:1984;2281-2296.
308. Strange P.G., Vile J.M. D4 receptors and schizophrenia. J. Neurochem. 65:1995;2381-2382.
309. Sunahara R.K., Guan H.C., O'Dowd B.R., Seeman P., Laurier L.G., Ng G., George S.R., Torchia J., Van Tol H.R., Niznik H.B. Cloning of the gene for a human doparaine D5 receptor with higher affinity for dopamine than D1. Nature. 350:1991;614-619.
310. Swerdlow N.R., Geyer M., Braff D., Koob G.F. Central dopamine hyperactivity in rats mimics abnormal acoustic startle in schizophrenics. Biol. Psychiat. 21:1986;23-33.
311. Swerdlow N.R., Geyer M.A. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol. Biochem. Behav. 44:1993;741-744.
312. Swerdlow N.R., Keith V.A., Braff D.L., Geyer M.A. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J. Pharmacol. Exp. Ther. 256:1991;530-536.
313. Swerdlow N.R., Mansbach R.S., Geyer M.A., Pulvirent L., Koob G.F., Braff D.L. Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology. 100:1990;413-420.
314. Tamminga, C.A.; Gerlach, J. New neuroleptics and experimental antipsychotics in schizophrenia. In: Meltzer, H.Y., ed. Psychopharmacology: the third generation of progress. New York: Raven Press; 1988:1129-1140.
315. 3H)acetylcholine release in rat striatal slices. Eur. J. Pharmacol. 211:1992;169-176.
316. Todd R.D., Kuhrana T.S., Sajovic P., Stone K.R., O'Malley K.L. Cloning of ligand-specific cell lines via gene transfer: identification of a D2 dopanidne receptor subtype. Proc. Natl Acad. Sci. USA. 86:1989;10134-10138.
317. Tschanz J.T., Rebec G.V. Atypical antipsychotic drugs block selective components of amphetamine-induced stereotype. Pharmacol. Biochem. Behav. 31:1989;519-522.
318. Undie A.S., Friedman E. Differences in the cataleptogenic actions of SCH 23390 and selected classical neuroleptics. Psychopharmacology. 96:1988;311-316.
319. Valenstein E.S. Problems of measurement and interpretation with reinforcing brain stimulation. Psychol. Rev. 71:1964;415-437.
320. Van Groll B.J., Appel J.B. Stimulus effects of d-amphetamine 1: DA mechanisms. Pharmacol. Biochem. Behav. 43:1992;967-973.
321. Van Tol H.H., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
322. Vanover K.E., Piercey M.R., Woolverton W.L. Evaluation of the reinforcing and discriminative stimulus effects of cocaine in combination with (+)-AJ 76 or clozapine. J. Pharmacol. Exp. Ther. 266:1993;780-789.
323. Vasse M., Protais P. Increased grooming behavior is induced by apomorphine in mice treated with discriminant benzamide derivatives. Eur. J. Pharmacol. 156:1988;1-11.
324. Villanueva H.F., Arezo S., Rosecrans J.A., Porter J.H. Discriminative stimulus properties of clozapine. Soc. Neurosci. Abstr. 16:1990;248.
325. Waddington J.L. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. Int. Rev. Neurobiol. 31:1989;297-353.
326. Waddington J.L. Spontaneous orofacial movements induced in rodents in very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology. 101:1990;431-447.
327. Waddington J.L., Cross A.J., Gamble S.J., Bourne R.C. Spontaneous orofacial dyskinesia and dopaminergic function in rats after six months of neuroleptic treatment. Science. 220:1983;530-532.
328. Waddington J.L., O'Boyle K.M. Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D1 antagonist. Pharmac. Ther. 43:1989;1-52.
329. Wadenberg M.L. Antagonism of 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J. Neural. Transm. 89:1992;49-59.
330. Wauquier A. Neuroleptics and brain self-stimulation behaviors. Int. Rev. Neurobiol. 21:1979;335-403.
331. Wauquier A., Niemegeers C.J.E. Intracranial self-stimulation in rats as a function of various stimulus parameters. II. Influence of haloperidol, pimozide and pipamperone on medial forebrain stimulation with monopolar electrodes Psychopharmacologia. 27:1972;191-202.
332. Wenger G.R. Effects of clozapine, chlorpromazine and haloperidol on schedule-controlled behavior. Pharmacol. Biochem. Behav. 11:1979;661-667.
333. White F.J., Wang R.Y. Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sci. 32:1983;983-993.
334. White I.M., Ciancone M.T., Haracz J.L., Rebec G.V. A lever-release version of the conditioned avoidance response paradigm: effects of halopeddol, clozapine, sulpiride, and BMY-148-2. Pharmacol. Biochem. Behav. 41:1991;29-35.
335. White I.M., Rebec G.V. Performance on a lever-release, conditioned avoidance task involves both dopamine D1 and D2 receptors. Eur. J. Pharmacol. 253:1994;167-169.
336. Wickens, J.R. A theory of the striatum. Oxford: Pergamon Press; 1993.
337. Wiley J.L., Compton A.D., Porter J.H. Effects of four anti-psychotics on punished responding in rats. Pharmacol. Biochem. Behav. 45:1993;263-267.
338. Wiley J.L., Porter J.H. Differential effects of haloperidol and clozapine on the reinforcing efficacy of food reward in an alleyway reacquisition paradigm. Pharmacol. Biochem. Behav. 36:1990;569-573.
339. Wiley J.L., Porter J.H. Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure. Pharmacol. Biochem. Behav. 43:1992;961-965.
340. Wiley J.L., Porter J.H., Faw W.R. Haloperidol blocks reacquisition of operant running during extinction following a single priming trial with food reward. Bull. Psychonom. Soc. 27:1989;340-342.
341. Wise R.A., Bozarth M. A psychomotor stimulant theory of addiction. Psychol. Rev. 94:1987;469-492.
342. Wise R.A., Rompre P.P. SCH 23390 shifts the self-stimulation rate-frequency function of 0.6 log units. Soc. Neurosci. Abstr. 14:1988;1102.
343. Wise R.A., Spindler J., de Wit H., Gerber J.G. Neuroleptic induced 'anhedonia' in rats: pimozide blocks reward quality of food. Science. 201:1978;262-264.
344. Woolverton W.L. Effects of a D1 and a D2 dopantine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol. Biochem. Behav. 24:1986;531-535.
345. Worms, P.; Broekkamp, C.L.E.; Lloyd, K.G. Behavioral effects of neuroleptics. In: Coyle, J.T.; Enna, S.J., eds. Neuroleptics: neurochemical, behavioral and clinical perspectives. New York: Raven Press; 1983:93-117.
346. Yokel R.A., Wise R.A. Attenuation of intravenous amphetan-tine reinforcement by central dopamine blockade in rats. Psychopharmacology. 48:1976;311-318.
347. Zarevics P., Weidley E., Setler P. Blockade of intracranial self-stimulation by antipsychotic drugs: failure to correlate with central alpha-noradrenergic blockade. Psychopharmacology. 53:1977;283-288.